Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kalos

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Cancer Immunology Research|January 21, 2015
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cellsMatthew J Frigault, Jihyun Lee, Maria Ciocca Basil, et al.
The New England Journal of Medicine|March 7, 2014
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIVPablo Tebas, David Stein, Winson W Tang, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Cell Reports|March 15, 2018
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint BlockadeDavid A Schaer, Richard P Beckmann, Jack A Dempsey, et al.
Transplantation and Cellular Therapy|February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory HurdlesKedar Kirtane, Michael Kalos, Rocky Billups, et al.
Molecular Cancer Therapeutics|April 4, 2020
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor ImmunityHelen Kotanides, Rose Marie Sattler, Maria B Lebron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cellsAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.
Blood|December 25, 2012
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIVPablo Tebas, David Stein, Gwendolyn Binder-Scholl, et al.
Blood|June 18, 2013
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaGerald P Linette, Edward A Stadtmauer, Marcela V Maus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer ImmunotherapyDavid A Schaer, Sandaruwan Geeganage, Nelusha Amaladas, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Cancer Immunology Research|January 21, 2015
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cellsMatthew J Frigault, Jihyun Lee, Maria Ciocca Basil, et al.
The New England Journal of Medicine|March 7, 2014
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIVPablo Tebas, David Stein, Winson W Tang, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Cell Reports|March 15, 2018
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint BlockadeDavid A Schaer, Richard P Beckmann, Jack A Dempsey, et al.
Transplantation and Cellular Therapy|February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory HurdlesKedar Kirtane, Michael Kalos, Rocky Billups, et al.
Molecular Cancer Therapeutics|April 4, 2020
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor ImmunityHelen Kotanides, Rose Marie Sattler, Maria B Lebron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cellsAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.
Blood|December 25, 2012
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIVPablo Tebas, David Stein, Gwendolyn Binder-Scholl, et al.
Blood|June 18, 2013
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaGerald P Linette, Edward A Stadtmauer, Marcela V Maus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer ImmunotherapyDavid A Schaer, Sandaruwan Geeganage, Nelusha Amaladas, et al.
Pageof 8